AlphAIalphai — Financial news for AI agents
MarketBeatMAY 13 min read$NSP

Insperity (NYSE:NSP) Updates Q2 2026 Earnings Guidance

Insperity (NYSE:NSP) has updated its Q2 2026 earnings per share guidance to $0.020-$0.500, with full-year 2026 EPS guidance set at $1.600-$2.600. The company recently beat Q1 estimates with $1.31 EPS and $1.90 billion in revenue. Despite a negative P/E ratio and net margin, insiders have shown recent buying activity, and the company offers a quarterly dividend with a 6.8% yield.

Original reporting
MarketBeat · MarketBeat
Published May 1, 2026, 1:39 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai May 1, 2026, 2:00 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
Insperity (NYSE:NSP) Updates Q2 2026 Earnings Guidance — source image
Source · MarketBeat
Decision brief

The 30-second read

$NSPNeutralMed
01

Why it matters

Guidance revision signals management's confidence, which could attract investor interest, but valuation metrics warrant caution.

02

Market read

The news is moderately relevant for traders focusing on the HR services sector and income-oriented strategies, with limited broader market impact.

03

What to watch

Potential macroeconomic headwinds or sector-specific risks could dampen stock performance despite positive guidance.

Timing: short to medium term (next 1-3 months)

Background

Insperity, a provider of HR and business performance solutions, has experienced recent volatility amid sector-wide concerns and valuation debates.

Company-level read

Ticker impact

$NSPNeutralMedium confidence
Context

Primary focus of the news due to earnings guidance update.

Expected impact

Potential modest positive movement in stock price following guidance update, contingent on market interpretation of earnings outlook.

Evidence & confidence

The guidance revision and recent earnings beat indicate positive momentum, but negative valuation metrics and overall market conditions introduce uncertainty.

Market effects

Sector

The update may positively influence the professional services and HR solutions sectors, especially if Insperity's performance outpaces industry peers.

Regional

Limited regional impact; primarily relevant to US markets where Insperity operates.

Global

Low; company-specific news with minimal direct global market implications.

Counterpoint

What could challenge this read

The negative P/E ratio and slim profit margins suggest the stock may be overvalued or facing structural challenges, cautioning against aggressive buying.

Key entities

  • Company
    Insperity Inc.

    A provider of human resources and business performance solutions.

Read at source← All news

Related articles

JUL 31
$NSPMedAI 8/10

Insperity (NSP) Stock Trades Down, Here Is Why

Insperity (NYSE: NSP) shares fell about 7.3% after its Q2 results and full-year guidance. The company reported adjusted EPS above its midpoint, but benefits costs per covered employee rose 5.2% and total gross profit fell 3%. Guidance also pointed to paid worksite employees declining about 1% to 1.6% in 2026.

financialcontent.com5 min
JUL 29
$NSPMed

Insperity (NYSE:NSP) Surprises With Q2 CY2026 Sales

Insperity (NYSE:NSP) reported Q2 CY2026 revenue of $1.69 billion, up 1.7% year over year, beating Wall Street’s revenue estimate by 0.7%. Non-GAAP adjusted EPS was $0.34, up from $0.26, and 6.9% above consensus. The article cites full-year EPS expected to rise from $0.85 to $2.34.

financialcontent.com6 min
JUL 29
$NSPMed

INSPERITY, INC. (NSP): Results of Operations and Financial Condition

INSPERITY, INC. (NSP) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Insperity Announces Second Quarter Results HOUSTON – July 29, 2026 – Insperity, Inc. (NYSE: NSP), a leading provider of human resources and business performance solutions for America’s best businesses, today reported results for the second quarter ended June 30, 2026

SEC EDGAR 8-K6 min
SEP 8
$BNTXMed

BioNTech Ended a Cancer Vaccine Trial. What Does it Mean for its mRNA Strategy?

BioNTech (NASDAQ:BNTX) halted a mid-stage trial of its mRNA cancer vaccine, autogene cevumeran, due to an overall survival imbalance. The decision raises concerns about its mRNA strategy in colorectal cancer and other 'cold' tumors. BioNTech plans to continue other trials, including one for pancreatic cancer and BNT113 for head and neck cancer. The company also focuses on diversifying its oncology pipeline. According to Reuters, the news caused a 7.5% drop in BioNTech's US-listed shares.

yahoo.com3 min
SEP 8
$VOW3.DEMed

HISTORIC TURN: Volkswagen To Produce Components For Israel’s Iron Dome System In Germany

Volkswagen (VW) plans to produce components for Israel's Iron Dome missile defense system at its Osnabrück, Germany factory. The move is part of VW's restructuring efforts amid economic challenges and competition. The project involves a joint venture with Israeli defense company Rafael and the German state of Lower Saxony, aiming to overcome opposition from Qatar's sovereign wealth fund, a VW stakeholder. This marks VW's return to defense-related manufacturing as European defense spending rises.

theyeshivaworld.com2 min
SEP 8
$XOMMed

Piper Sandles Sees ExxonMobil (XOM) Heading Toward New Highs

Piper Sandler raised its price target for ExxonMobil (XOM) to $185, citing strong fundamentals, cost savings, and growth in Guyana. XOM's Q2 earnings beat expectations, with high free cash flow and shareholder returns. However, risks include exposure to Middle East conflicts and potential crude price normalization. XOM's stock has risen 30% in 2026, with a 16% upside implied by the new target.

yahoo.com2 min